Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib versus TNF inhibitors for venous thromboembolism risk in rheumatoid arthritis
NL-OMON61085Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2019
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of baricitinib in rheumatoid arthritis (RA) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Time from first dose of study treatment to first event of venous thromboembolism. Started Sep 2019; status: completed.
02
Drugs
baricitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON61085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61085.